Extended spectrum beta-lactamse (ESBL)-induced antibiotics resistance in gram-negative agents: What should be watched in intensive care medicine?;Extended spectrum beta-laktamase (ESBL)-vermittelte antibiotikaresistenz bei gramnegativen erregern: Was ist in der intensivmedizin zu beachten?

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 38, Issue 9, 2003, Pages 573-576

  Kola, Axel ^a   Gastmeier, P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibiotic; ESBL; Prevention; Resistance

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFOTETAN; CEFOXITIN; ERTAPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL METABOLISM; DRUG DEGRADATION; ESCHERICHIA COLI; HUMAN; INTENSIVE CARE; KLEBSIELLA PNEUMONIAE; REVIEW;

BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE;

EID: 0141792440     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41859     Document Type: Review

References (23)

1. Knothe H, Shah P, Kremery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandol and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-317
2. Lucet JC, Decre D, Fichelle A, et al. Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriacae in a university hospital. CID 1999; 29: 1411-1418
3. Paterson DL, Singh N, Rihs JD, et al. Control of an outbreak of infection due to extended-spectrum β-lactamase-producing Escherichia coli in a liver transplantation unit. CID 2001; 33: 126-128
4. Paterson DL. Extended-spectrum β-lactamases: the European experience. Curr Opin Infect Dis 2001; 14: 697-701
5. Paterson DL. Recommendation for the treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-463
6. Lautenbach E, Storm B L, Bilker WB, et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. CID 2001; 33: 1288-1294
7. Kim BH, Woo JH, Kim MN, et al. Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteriaemia. J Hosp Infect 2002; 52: 99-106
8. Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28: 1718-1723
9. Rice LB. Successful interventions for gram-negative resistance to extended-spectrum β-lactam antibiotics. Pharmacotherapy 1999; 19: 120S-128S
10. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to K. pneumoniae producing extended-spectrum β-lactamases. Antimicrob. Agents Chemother 1998; 42: 53-58
11. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in southern and western europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183-189
12. Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU study groups. JAMA 1999; 281: 67-71
13. Perilli M, Dell'Amicod E, Segatore B, et al. Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J Clin Microbiol 2002; 40: 611-614
14. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA, (für die Studiengruppe). Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfung und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2001. Antiinfectives Intelligence, Bonn, 2003
15. st century: Characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951
16. Meyer E, Jonas D, Schwab F, et al. Design of a surveillance system of antibiotic use and bacterial resistance in german intensive care units (SARI). Infection, accepted for publication.
17. Witte W, Klare I. Enterobakterien verstärkt resistent durch Breitspektrum-β-Laktamasen (ESBL). Epi Bull 2002; 8: 63-64
18. Smith ME, Hanson ND, Herrera VL, et al. Plasmid-mediated, carbapenem-hydrolising beta-lactamase KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003; 51: 711-714
19. Hospital Infection Control Advisory Committee. Guidelines for isolation precautions in hospitals. Am J Inf Control 1996; 24: 24-52
20. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to K. pneumoniae producing extended-spectrum β-lactamases. Antimicrob. Agents Chemother 1998; 42: 53-58
21. Patterson JE. Antibiotic utilization - is there an effect on antimicrobial resistance? Chest, 2001; 119: S426-S430
22. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: Are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? CID 2003; 36: 1006-1012
23. Thomson KS. Controversies about extended-spectrum and AmpC-beta-lactamases. Emerg. Infect. Dis. 2001; 7: 333-336. Anonym.